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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The outcomes and their predictors, and rates of estimated glomerular
filtration rate (eGFR) changes among Taiwanese, an ethnic Chinese population, with chronic
kidney disease (CKD) stages 3be5, enrolled in a nationwide pre-end-stage renal disease
(pre-ESRD) management program that have not been previously reported.
Methods: This study focused on a cohort of patients enrolled in the Taiwan’s pre-ESRD disease
management program from Southern Taiwan, including 4061 CKD 3be5 patients who received
more than 12 weeks of follow-up from 2007 to 2010. The decline rates of eGFR, outcomes, and
the predictors of initiating dialysis were analyzed.
Results: The study participants consisted of patients who were 70.1  12.3 years old, of whom
56.4% were male, 46.3% were diabetic, and 72.1% were hypertensive. The mean annual eGFR
changes were 0.47  0.42 mL/min/1.73 m2/year, 1.27  0.32 mL/min/1.73 m2/year, and
2.69  0.39 mL/min/1.73 m2/year for stages 3b, 4, and 5, respectively; however, more rapid
declines were noted in diabetic patients. The KaplaneMeier analyses revealed that the prob-
abilities of patients remaining alive and free of dialysis treatment for CKD stage 3b, 4, and 5
without or with diabetes were 89.46% versus 84.65%, 79.88% versus 55.68%, and 34.42% versusephrology, Department of Internal Medicine, National Cheng-Kung University Hospital, 138 Shing-Li
.ewdu.tw (J.-M. Sung).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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774 C.-M. Lin et al.9.64%, respectively, during 42 months of follow-up. Male gender, diabetes, lower baseline
eGFR, higher systolic blood pressure, lower hematocrit, and albumin levels were the significant
risk factors for initiating dialysis.
Conclusion: Even though we cannot conclude with certainty that the Taiwan pre-ESRD disease
management program is beneficial in slowing the progression of CKD stages 3be5, our prelim-
inary results seem to suggest this trend. Furthermore, the program may be improved by inte-
grating it with other programs, such as those on diabetes and hypertension, thus making it a
more patient-centered, multidisciplinary program.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Treatments for end-stage renal disease (ESRD) are costly
and represent a growing burden on healthcare systems;
therefore, the adequate management of chronic kidney
diseases (CKDs) to slow the incidence and progression of
this condition is of considerable interest.1e3 This is espe-
cially true in Taiwan, which has a universal health insurance
system [Taiwan National Health Insurance (Taiwan NHI)]
and the highest prevalence and incidence of ESRD in the
world.4 According to the Taiwan Bureau of National Health
Insurance (TBNHI), the costs associated with ESRD amoun-
ted to US$1.17 billion in 2009, which is approximately 8% of
the total annual health insurance expenditure.5
CKD is also associated with high mortality and morbidity,
which are mainly associated with cardiovascular diseases
(CVDs).6 Slowing the progression of CKD can reduce com-
plications and improve both survival and quality of life of
patients,7e9 and this might be achieved with the develop-
ment and application of disease management pro-
grams.10e16 Recently, Jia et al17 showed the beneficial
effects of a multidimensional education program held for
302 Chinese patients with CKD stages 3be5. However,
relatively few studies have reported the results of national
disease management programs that focus on CKD.
Taiwan’s pre-ESRD disease management program was
established in November 2006 by the TBNHI,18 and combines
nephrology, nursing, and dietary counseling, along withdif
necessarydcounseling by professionals from other disci-
plines, such as cardiology. The content of the program was
standardized in accordance with the National Kidney Foun-
dation/KidneyDiseaseOutcomesQuality Initiative guidelines.
Wu et al19 and Chen et al20 reported that this program has
managed to decrease the incidence of dialysis and reduce
mortality, although both studies were based on small pro-
portions of the patients enrolled in the program, and to date
there remains limited knowledge about the results for large
cohorts of patients enrolled in national pre-ESRD programs. It
is worth noting that the risk factors for poor patient outcomes
under a diseasemanagement programmay not be the sameas
those for patients not enrolled in such aprogram. In this study,
we obtained the relevant knowledge related to the progres-
sion from CKD to ESRD in the pre-ESRD disease management
program from Taiwan’s NHI database. The aims of this study
are to investigate changes in the estimated glomerular
filtration rate (eGFR) and the predictors of initiating dialysis
therapy among patients with CKD stages 3be5, enrolled in
Taiwan’s pre-ESRD disease management program.Patients and methods
Taiwan pre-ESRD disease management program
The program’s goals are to decrease the incidence of ESRD,
as well as the morbidity and mortality of CKD. Specifically,
the program aims to improve the early detection rate of
CKD, to facilitate identification of patients at high risk of
progressing to ESRD or pre-ESRD death, and to promote
evidence-based interventions. In addition, the program also
aims to help pre-ESRD patients to initiate dialysis and to
reduce both the use of emergency care and hospitalization
costs.19e21 The program is provided by a multidisciplinary
team, including nephrologists, renal nurses, and dieticians,
to care for patients with different CKD stages, as measured
by a specific function of the kidneys, known as the Modifi-
cation of Diet in Renal Disease eGFR (calculated by the
Modification of Diet in Renal Disease abbreviated equa-
tion).22 This initiative includes the control of blood pressure
(BP), sugar, and lipid by the use of counseling and medi-
cation, prescription of a low protein diet, selection of
appropriate dialysis mode, early preparation of dialysis
access, and outpatient dialysis treatment.
Patients were enrolled in the pre-ESRD disease man-
agement program if they met the entry criteria and were
willing to participate. At the initial visits, the nephrologists
developed a patient care plan according to the Kidney
Disease Outcomes Quality Initiative guidelines,23 performed
renal function tests, and provided basic knowledge about
CKD and its treatment. The diagnosis of CKD was confirmed
by at least two eGFR determinations, the interval between
two data must be 28 days, and the care nephrologists
were responsible for excluding patients with acute kidney
injury (AKI) prior to registering. Specific counseling was
performed when registering the patient and at the subse-
quent visits, based on the needs of individual patients
during the follow-up period. Generally, patients with stages
3b, 4, and 5 CKD were followed up every 12 weeks, 8 weeks,
and 4 weeks, respectively, or when necessary. The blood
tests were performed every 12 weeks or when necessary.
Enrolled patients were followed up until death, or initialing
long-term dialysis, or loss of follow-up. Clinical character-
istics, such as age, sex, underlying diseases, comorbidities,
BP, and laboratory data [including serum albumin, creati-
nine, and hematocrit (Hct) levels, and eGFR], were sub-
mitted to the TBNHI via a secure virtual private network
every 12 weeks. The patients’ fasting blood lipid, uric acid,
sodium, potassium, calcium, phosphate, sugar, and
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at least once every year. It should be noted that these data
were used for patient care and counseling, but not sub-
mitted to the TBNHI. Every patient whose information was
submitted successfully to the TBNHI and satisfied the
related requirements was reimbursed for this program. In
addition, the patients’ details when reaching the endpoint
of the program were also submitted to the TBNHI. With
regard to individual patients, the interval between every
reimbursement should be more than 77 days, except for the
reimbursement on reaching the endpoint.
Study patients and data extraction
The study patients were drawn from a multicenter cohort
drawn from 27 predialysis clinics (i.e., nephrologists) or
general/university-affiliated hospitals contracted with the
TBNHI from 2007 to 2010 in Southern Taiwan, which con-
tains two cities and two counties, and covers 3.2 million
residents. Demographic and laboratory data were collected
from the patients’ data submitted to the TBNHI via a secure
virtual private network. CKD stage was determined
following the method used by the National Kidney Foun-
dation of the United States. At the time of entry, eGFRs of
30e45 mL/min/1.73 m2, 29e15 mL/min/1.73 m2, and
<15 mL/min/1.73 m2 were classified as CKD stages 3b, 4,
and 5, respectively. The observation period for each pa-
tient was defined as starting immediately after the regis-
tered measurement of eGFR satisfying the above criteria
(designated as the index date), and until ESRD, or pre-
dialysis death, or loss of follow-up. As there is no consistent
definition for “loss of follow-up” with regard to the Taiwan
pre-ESRD program during the study period, we arbitrarily
defined this as not uploading data more than 1 year prior to
the end of the current study period (December 30, 2010) in
patients who did not develop ESRD or suffer a pre-ESRD
death.
Patients who had enrolled in a pre-ESRD program were
identified as those who had submitted medical claims that
included at least one of the following procedure payment
codes, namely, P3402C, P3403C, P3404C, and P3405C,
during the period from 2007 to 2010. ESRD was defined as
initiation of renal replacement therapy, that is, chronic
dialysis or kidney transplantation. However, none of the
enrolled patients received preemptive kidney trans-
plantation in Southern Taiwan during the study period. The
timing to initiate renal replacement therapy follows the
regulations set by the TBNHI, including creatinine clear-
ance <15 mL/min or serum Cr >6 mg/dl, plus any of the
following conditions: (1) blood urea nitrogen >100 mg/dl;Figure 1 Flow chart of the derivation of study coho(2) refractory heart failure, lung edema, metabolic
acidosis, or hyperkalemia; (3) pericarditis; (4) bleeding
tendency; (5) uremic encephalopathy or neuropathy; or (6)
uncontrolled nausea, vomiting, or cachexia. Using the
TBNHI’s pre-ESRD database enabled this study to obtain
data on all the patients who were enrolled in the pre-ESRD
program and had an estimated GFR of <45 mL/min/1.73 m2
in Southern Taiwan. Fig. 1 shows the derivation of the
cohort based on the available records. Generally, a regis-
tered eGFR <45 mL/min/1.73 m2 per patient was consid-
ered the index result from which we started the follow-up
analysis. To ensure the appropriate inclusion of CKD pa-
tients with adequate follow-up for the analysis of interest,
we excluded patients who had less than two eGFR results
after the first registration (nZ 752). Patients with a second
set of eGFR data submitted to the TBNHI should have
received multidisciplinary care from this program for at
least 12 weeks. When establishing the study cohort, those
patients with possible AKI, who were arbitrarily defined as
patients who had differences between the second eGFR
data and registered eGFR data (obtained with an interval
that ranged from 12 weeks to 24 weeks) of more than 25%,
or 50% of the registered eGFR every 12 weeks {calculated by
the equation: [12 change of eGFR (%)]/the interval be-
tween the second eGFR and registered eGFR (weeks)}, in
patients enrolled with CKD stage 3b or stages 4e5, or pa-
tients who commenced chronic hemodialysis therapy within
12 weeks after enrollment, were also excluded to avoid the
confounding of AKI when enrolled (nZ 51). Although some
of these 51 patients may have been CKD patients with rapid
progression, this would not significantly change the results
of the present study because of the small number of
affected patients. In addition, patients whose second visit
and eGFR data were more than 24 weeks after the regis-
tration were arbitrarily defined as possibly noncompliant
patients, and were also excluded from the final analyses
(n Z 95). The baseline demographic data and clinical
characteristics of the excluded patients were compared
with those included in the follow-up group according to CKD
stages, and no significant differences were found. Finally,
during a cumulative follow-up of 7213 patient-years in this
cohort, there were 558 dialysis initiations (484 hemodialysis
and 74 peritoneal dialysis), 94 deaths, and 795 loss of
follow-up (Fig. 1). The variables used in the analyses for
initiating dialysis included demographics, such as age and
sex, as well as various laboratory variables, such as Hct,
serum albumin and creatinine, BP, and comorbidities, such
as diabetes, CVD, and hypertension. Urine protein loss data
were not recorded in the early phase (from year 2007 to
2010) of this program.rt. HD Z hemodialysis; PD Z peritoneal dialysis.
Table 1 Patient characteristics by baseline stage of CKD.a
Variables All Stage 3b Stage 4 Stage 5 p
n Z 4061 n Z 1040 n Z 1773 n Z 1248
(26%) (44%) (30%)
Age (y) 70.1  12.3 70.5  12.0 70.9  12.3 68.8  12.5 0.001
Sex
Male 56.4 71.3 56.7 43.9 <0.001
Past medical history
Diabetes 46.3 42.0 50.1 44.6 <0.001
Hypertension 72.1 69.2 73.0 73.2 0.006
Cardiovascular diseases 12.7 12.9 13.4 11.5 0.316
Systolic BP (mmHg) 137.7  20.4 135.5  20.0 137.3  20.3 139.9  20.7 <0.001
Diastolic BP (mmHg) 76.2  12.2 76.7  12.5 75.9  12.2 76.2  12.0 0.462
Hematocrit 32.9  6.1 37.7  5.5 33.17  5.2 28.4  4.7 <0.001
Serum albumin (g/dL) 3.9  0.6 4.0  0.5 3.8  0.6 3.8  0.6 <0.001
Serum creatinine (mg/dL) 3.4  2.0 1.8  0.3 2.8  0.9 5.7  1.9 <0.001
eGFR (mL/min/1.73 m2) 22.4  11.0 37.3  4.4 22.5  4.3 10.1  2.9 <0.001
Follow-up (mo) 15.0  10.9 12.5  7.5 17.9  12.1 13.0  10.5 <0.01
Data are expressed as mean  standard deviation or %, unless otherwise indicated.
ANOVA Z analysis of variance; BP Z blood pressure; CKD Z chronic kidney disease; eGFR Z estimated glomerular filtration rate.
a Statistical tests are done by Chi-square test and one-way ANOVA to examine categorical and continuous variables, respectively, with
p < 0.05 indicating statistical significance.
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Datawere expressed asmeans (SD or SE) or percentages (n).
We tested for differences using Chi-square tests and one-way
analysis of variance to examine the categorical and contin-
uous variables, respectively, with p < 0.05 indicating statis-
tical significance. The associations of presumed risk factors
with initiating dialysis were analyzed by the Cox proportional
hazards model. The proportional hazards assumption was
checked using log-minus-log plots, and accepted as not
violated. To calculate the rate of eGFR decline, the first
registered and latest available serum creatinine data were
used. Statistical analysis was conducted using the JMP Base,
version 9.0.0 (SAS Campus Drive, Cary, NC, USA).
Results
Baseline demographic characteristics
A total of 4061 patients with a mean age of 70.1 were
enrolled in the program and were available for analysis. The
median follow-upwas 12months (25the75th percentile, 6e20
months). Table 1 gives the baseline characteristics of the
population cohort. At the start of the study, 1040 (26%) pa-
tients were at stage 3b, 1773 (44%) patients were at stage 4,
and 1248 (31%) patients were at stage 5. There were slightly
more male patients than female ones (56.4%). Of the total
patients, 46.3% had diabetes, 72.1% had hypertension, and
12.7% had CVD. More male patients were at stage 3b, but the
percentages becomemore balanced at stages 4e5. Although
statistically significant, there was no substantial difference
in the prevalence of hypertension across the three CKD
stages. Patients with stage 3b had significantly lower systolic
BP, and higher Hct and serum albumin levels when compared
with patients with stages 4 and 5 CKD.Patient’s outcomes during follow-up
Among the 4061 patients, 1626 patients received follow-up
2 years or reached endpoints of ESRD or predialysis death
within 2 years. There were no significant differences in the
baseline characteristics between these 1626 patients and
the rest of those in each subgroup of the cohort (Table S1 in
the supplementary material online). Fig. 2A shows the 2-
year cumulative outcomes of the cohort (n Z 1626). It
can be seen that 0.2%, 17.5%, and 64.7% of the patients
progressed to ESRD, necessitating dialysis treatment for
those with baseline CKD stages 3b, 4, and 5, respectively.
The percentages of patients who had improved CKD staging
or stayed at the baseline stage were 75.1%, 54.5%, and
29.4% for stages CKD 3b, 4, and 5, respectively. Fig. 2B
demonstrates the patient outcomes of the whole cohort by
months and grouped by baseline stages of CKD (n Z 4061).
Table 2 summarizes the annual rate of change in annual
eGFR (mL/min/1.73 m2/year) and clinical outcomes for the
4061 patients by baseline CKD stages. The mean annual
changes in eGFR were 0.47 mL/min/1.73 m2, 1.27 mL/
min/1.73 m2, and 2.69 mL/min/1.73 m2 for stages 3b, 4,
and 5, respectively. The eGFR changes were greater for
patients with diabetes compared to those without diabetes
among CKD stages 3b, 4, and 5, being 2.06 mL/min/
1.73 m2 versus 2.29 mL/min/1.73 m2, 2.45 mL/min/
1.73 m2 versus 0.11 mL/min/1.73 m2, and 3.77 mL/min/
1.73 m2 versus 1.70 mL/min/1.73 m2/year, respectively.
Fig. 3 shows themean rate of decline in annual eGFR. The
annual eGFRs skewed to the left, with a fast declining slope
for patients with diabetes. In addition, the cohort with dia-
betes had a mean eGFR rate of decline of 1.91 mL/min/
1.73 m2/year, with a median of 2 mL/min/1.73 m2/year,
and the 25the75th percentile declined from 5.0 to 0. By
comparison, the patients without diabetes had a mean eGFR
rate of decline of 0.31 mL/min/1.73 m2/year, with a
Figure 2 (A) Two-year cumulative outcomes grouped by baseline stages of CKD (n Z 1626) and (B) the patient outcomes of the
whole cohort by months and grouped by baseline stages of (n Z 4061). CKD Z chronic kidney disease; HD Z hemodialysis;
PD Z peritoneal dialysis.
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percentile declined from 3.0 mL/min/1.73 m2 to 1 mL/
min/1.73 m2/year.
With regard to the 95 patients with possible noncom-
pliance, “loss of follow-up” was noted in 50 (52.6%) pa-
tients, which was a greater proportion than that seen in the
overall study population (19.6%, 795 among 4061 patients),
suggesting poor adherence to the program in these pa-
tients. The baseline characteristics of these patients are
shown in Table S2 (see the supplementary material online),
and it can be seen that there were no statistically signifi-
cant differences when comparing the rates of eGFR changes
of these patients with those of the corresponding groups in
the study population (Table S3 in the supplementary ma-
terial online), although the decline rate of eGFR for the
stage 4 possibly noncompliant patients tended to be more
rapid.Fig. 4 shows the KaplaneMeier curves for nondialysis
treatment and being alive in patients among CKD stages
3be5 with and without diabetes. The probabilities of pa-
tients remaining alive and free of dialysis treatment for
CKD stages 3b, 4, and 5 without or with diabetes were
89.46% versus 84.65%, 79.88% versus 55.68%, 34.42% versus
9.64%, respectively, during 42 months of follow-up (all
p < 0.05 except for patients with CKD stage3b). Further-
more, the probability of patients remaining alive and free
of dialysis was significantly different only between CKD
stage 4 patients with or without hypertension (Fig. 5). The
KaplaneMeier results analyzing the effects of the presence
of diabetes or hypertension on the outcome of either
nonpredialysis death or not reaching ESRD are shown in
Figs. S1e4 (see the supplementary material online). It can
be seen that diabetes or hypertension had no significant
impacts on the outcome of pre-ESRD death, which might be
Table 2 Clinical outcomes of patients by baseline CKD stages.a
Variables All Stage 3b Stage 4 Stage 5 p
n Z 4061 n Z 1040 n Z 1773 n Z 1248
100% 25% 44% 31%
eGFR change (mL/min/1.73 m2/y)
With diabetes 2.06  0.73 2.45  0.51 3.77  0.65 0.158
Without diabetes 2.29  0.49 0.11  0.4 1.70  0.46 <0.001
All 0.47  0.42 1.27  0.32 2.69  0.39 <0.001
Dialysis treatment 13.7 (558) 0.2 (2) 8.9 (158) 31.9 (398) <0.001
Dialysis/per 100 patient-years 7.94 0.13 4.53 20.31 <0.001
Death 2 (94) 1 (11) 2 (41) 3 (42) <0.001
Death/per 100 patient-years 1.34 0.70 1.18 2.14 <0.001
Data are expressed as means  standard error or % (n).
ANOVA Z analysis if variance; CKD Z chronic kidney disease; eGFR Z estimated glomerular filtration rate.
a Statistical tests are done by Chi-square test and one-way ANOVA to examine categorical and continuous variables, respectively, with
p < 0.05 indicating statistical significance.
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ESRD death in this cohort.
Estimate the proportion of patients with CKD stages
3be5 participating in the pre-ESRD program
Table S4 in the supplementary material online shows the
estimated number (proportion) of CKD stages 3be5 patients
participating in the pre-ESRD program in Southern Taiwan.
From January 2012 to December 2012, the number (pro-
portion) of incident dialysis patients in Southern Taiwan
were 8519 patients, among whom 3563 (42%) had joined
and had 2 visits to the pre-ESRD program prior to initiating
chronic dialysis (in-house analysis of the TBNHI database).
Predictors for dialysis treatment
The outcome of interest in Table 3 is ESRD, which is defined as
initiationof dialysis,with the time intervals of follow-upbeing
censored when patients had pre-ESRD mortality or a loss ofFigure 3 The distribution of annual estimated glomerular filtrati
The eGFR decline rate is more rapid in patients with diabetes, and
decline rates.follow-up prior to ESRD. Table 3 shows the baseline charac-
teristics that are significantly associated with the risk for
initiating dialysis treatment, as obtained by the multivariate
Cox proportional analysis. Lower baseline eGFR,male gender,
higher systolic BP, lower Hct, and lower albumin levels, and
having diabetes were all independent and significant risk
factors for reaching dialysis treatment in CKD stages 3be5
patients. However, diastolic BP and the presence of CVDwere
not significantly associated with the risk of dialysis. When
multivariate Cox analyses were performed for different
baseline CKD stages, the above risk factors were still inde-
pendently associated with reaching ESRD in stages 4 and 5
patients, but not in patients with CKD stage 3b, except for
albumin,whichmaybebecauseonly a small proportionofCKD
stage 3b patients progressed to ESRD in the current study.Discussion
This study analyzed the status of CKD progression in a
multicenter cohort who enrolled in a pre-ESRD diseaseon rate (eGFR) changes for patients with and without diabetes.
patients with diabetes have higher percentages of rapid eGFR
Figure 4 The KaplaneMeier curves show the probability of
non-dialysis and being alive for chronic kidney disease (CKD)
patients with or without diabetes in CKD stage 3b (log-rank test
indicates p Z 0.92 between the two groups, n Z 1040; upper
panel), in CKD stage 4 (log-rank test indicates p < 0.001 be-
tween the two groups, n Z 1773; middle panel), and in CKD
stage 5 (log-rank test indicates p < 0.001 between the two
groups, n Z 1248; lower panel).
Figure 5 The KaplaneMeier curves show the probability of
nondialysis and being alive of chronic kidney disease (CKD)
patients with or without hypertension in CKD stage 3b (log-rank
test indicates p Z 0.846 between the two groups, n Z 1040;
upper panel), in CKD stage 4 (log-rank test indicates pZ 0.014
between the two groups, nZ 1773; middle panel), and in CKD
stage 5 (log-rank test indicates p Z 0.376 between the two
groups, n Z 1248; lower panel).
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years, with amedian follow-up of 12months. Themean rates
of eGFR changewere 2.29mL/min/1.73m2/year,0.11mL/
min/1.73 m2/year, and 1.70 mL/min/1.73 m2/year for
nondiabetic patients with CKD stages 3b, 4, and 5, respec-
tively, and were 2.06 mL/min/1.73 m2/year, 2.45 mL/
min/1.73 m2/year, and 3.77 mL/min/1.73 m2/year fordiabetic patients. Because the Taiwan pre-ESRD disease
management program is a nationwide policy, rather than a
researchproject, itwas unethical to enroll patients as part of
a control group to study the beneficial effects of this pro-
gram. However, Chiu et al24 recruited 433 Taiwanese with
CKD from a medical center prior to when this pre-ESRD dis-
ease management program was initiated, and the results
Table 3 Multivariable Cox regression model for the effects of the baseline variables on the risk of dialysis treatment
(n Z 4061).a
Variables Stages 3be5
(n Z 4061)
Stage 3b
(n Z 1040)
Stage 4
(n Z 1773)
Stage 5
(n Z 1248)
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Baseline eGFR
(mL/min/1.73 m2)
0.88 0.86e0.89 <0.001 1.06 0.93e1.21 0.39 0.93 0.89e0.96 <0.001 0.85 0.82e0.88 <0.001
Age, per year increase 0.99 0.98e0.99 0.026 1.05 0.99e1.11 0.1 0.98 0.97e0.99 <0.001 0.99 0.99e1.01 0.86
Sex, male vs. female 1.69 1.44e1.99 <0.001 0.91 0.23e4.16 0.9 1.75 1.30e2.34 <0.001 1.73 1.42e2.11 <0.001
Systolic BP, per
mmHg increase
1.01 1.01e1.02 <0.001 1.01 0.98e1.04 0.43 1.02 1.01e1.02 <0.001 1.01 1.00e1.01 0.009
Hematocrit
(Hct), per %
0.96 0.94e0.97 <0.001 1.06 0.95e1.20 0.27 0.93 0.91e0.96 <0.001 0.97 0.95e0.99 0.005
Albumin, per g/dL 0.53 0.46e0.60 <0.001 0.13 0.05e0.35 <0.001 0.4 0.32e0.50 <0.001 0.63 0.53e0.74 <0.001
Diabetes, with vs.
without
1.7 1.45e2.01 <0.001 1.42 0.39e4.95 0.58 1.98 1.47e2.69 <0.001 1.65 1.36e2.01 <0.001
BP Z blood pressure; CI Z confidence interval; CVD Z cardiovascular disease; eGFR Z estimated glomerular filtration rate;
HR Z hazard ratio.
a Statistical tests are done by multivariable Cox regression to examine variables, respectively, with p < 0.05 indicating statistical
significance. Diastolic BP, and the presence of CVD are not significantly associated the risk of dialysis.
780 C.-M. Lin et al.showed an annual eGFR change of 2.05 mL/min/1.73 m2/
year, 3.77 mL/min/1.73 m2/year, and 2.83 mL/min/
1.73 m2/year in Taiwanese participants without diabetes
with CKD stages 3b, 4 and 5, respectively, and of
5.38 mL/min/1.73 m2/year, 4.98 mL/min/1.73 m2/year,
and5.10 mL/min/1.73 m2/year for patients with diabetes.
In addition, Hou et al25 showed an annual GFR decline of
3.2 mL/min to 5 mL/min in Chinese patients without
diabetes with stage 4 CKD. The eGFR declining rates for our
study cohort were slower than those reported by Chiu et al24
and Hou et al25; furthermore, the 2-year cumulative rate of
reaching ESRD or pre-ESRD death was also lower (Fig. 2) than
that seen for the patients in Chiu et al’s24 study. Although it
would difficult to conclude that rates are slower with the
program without making any direct comparisons with a his-
torical or control cohort, our data suggest that there are
some beneficial effects related to the Taiwan pre-ESRD dis-
ease management program with regard to the progression of
patients with stages 3be5 CKD. This tentative conclusion is
consistentwith the results of recent studies byWuet al19 and
Chen et al,20 which showed that the Taiwan pre-ESRD disease
management program can decrease the incidence of dialysis
and reduce mortality, by comparing selected patients
enrolled in the program with those who were not enrolled in
it. Furthermore, based on Fig. 2A, there were significant
proportions of stage reversaldfor example, from stage 3b to
stage 3a (19.3%) and from stage 4 to stage 3b (11.2%)din the
current study. Because we excluded patients with possible
AKI when enrolling, it is unlikely that the stage reversal could
be explained by this cohort being contaminated by AKI pa-
tients. The findings that referral to a nephrology clinic with
multidisciplinary care led not only to arresting or slowing the
progression of CKD, but also to regression and improvement
in a certain proportion of patients in the current study, are
consistent with the results of previous studies conducted by
Taskapan et al,26 Jones et al,2 and Zhang et al.27 The reasons
for these beneficial effects could be multifactorial, such as
changes in lifestyle, avoiding nephrotoxins,28 improvingdietary habits, and having a positive attitude and greater
compliance with medication regimens. To improve the allo-
cation of limited healthcare resources, different strategies
are required for each patient’s follow-up based on the
probability of progression. The risk factors associated with
the need for dialysis therapy in our cohort weremale gender,
lower baseline eGFR, higher systolic BP, having diabetes, and
lower Hct levels. Aging was protective of dialysis therapy in
the current study, consistent with the data reported in the
literature.29,30 We speculate that this might be because
aging patients were more compliant with regard to the sug-
gestions of this program. Nevertheless, the risk factors
identified in the current study should be taken into account
when developing “the probability of reaching the ESRD
score” to identify the patients in the CKD population who are
at high risk of accelerated renal function loss, thus enabling
the integration of a risk prediction tool as an intelligent
clinical decision support to aid in outpatient renal
care.16,30,31
In this cohort, patients with diabetes had an estimated
1.70-fold greater chance of requiring dialysis treatment
compared to those without diabetes. The probability of
patients remaining alive and not requiring dialysis treat-
ment for CKD stages 4 and 5 was also higher for those
without diabetes than those with it. Many countries have
identified diabetes as an independent risk factor for dialysis
treatment.4,32 Because progression of CKD to ESRD is a
continuous process, a loss in renal function in CKD patients
with diabetes is a significant cause of accelerated declines
in eGFR,24 and of the increased prevalence of ESRD in
Taiwan. Diabetes affects 6.2e8% of the Taiwanese popu-
lation aged over 40 years, and with the aid of NHI coverage
such individuals have access to healthcare, thus increasing
of the incidence of diabetic nephropathy,33 with fewer such
patients dying from other complications.34 Among CKD
stages 3be5, patients with diabetes thus serve as a pointed
reminder of the importance of the aggressive management
of diabetes,35,36 its complications, and the associated risk
Progression of CKD in Taiwan pre-ESRD program 781factors for progressive loss of eGFR, and the eventual need
for dialysis.37 The results also reinforce the importance of
and need for the greater involvement of endocrinologists
and diabetes nurses in the care of patients with CKD stages
4 and 5 who have diabetes, rather than leaving such work to
nephrologists, who may or may not be providing complete
care.38e40
The enrollment rate and adherence of the pre-ESRD
program are also important issues. From January 2012 to
December 2012, the proportion of incident dialysis patients
who received care under the pre-ESRD program prior to the
initiation of chronic dialysis therapy was 42%. The esti-
mated enrollment rate was 48% for CKD stage 5 patients in
Southern Taiwan from 2007 to 2010, suggesting that there
has been no significant improvement in enrollment in
recent years. Furthermore, during the study period, 752
patients in this program had only one set of eGFR data, and
795 of the 4061 patients in the study cohort had loss of
follow-up. These data underline the importance of devel-
oping strategies to increase the enrollment and adherence
of CKD patients.
The strengths of our study include its large sample
population of patients in CKD stages 3be5 who were
enrolled in the program, receiving routine care by
nephrology teams and multicenter clinics/hospitals in a
nonclinical trial setting. The data from these real cases can
thus help health policymakers better understand the pro-
gression among patients with CKD stages 3be5, and thus
leverage the pre-ESRD disease management claims data to
control the risk factors associated with accelerated de-
clines of eGFR (i.e., with the aim of preventing diabetes
and hypertension), in order to reduce the incidence of ESRD
in this program.
There are a number of practical and ethical restrictions
that preclude the use of randomized controlled trials in
evaluating the effectiveness of disease management pro-
grams. As a consequence, the findings of this observational
study need to be considered in the light of several limita-
tions. First, a potential selection bias might exist in this
cohort, because patients voluntarily enrolled in the pre-
ESRD disease management program and there was no con-
trol group. This might have caused the patients to more
closely follow the nephrologists’ predialysis instructions,
and lead to a slower rate of decline in eGFR than would
have been seen in patients who were not enrolled in such a
program. Second, the progression of the decline and sta-
bilization of eGFR shown in this work could be influenced by
different serum creatinine testing practices adopted by the
multicenter laboratories, although they all met the stan-
dards of the Taiwan Laboratory for Healthcare Quality
Regulation Policy. This may also have led to the possibility
of small errors in the eGFR calculation, and misclassifica-
tion of cases into different stages of CKD. Third, this study
did not gather data related to some important variables,
such as daily urine protein loss (or urine protein/creatinine
ratio), smoking habits, dyslipidemia, serum calcium, phos-
phate, sodium, and potassium levels, hemoglobin A1c data,
and type of antihypertensive agents used. Therefore, it can
be argued that the results presented in this work are
potentially biased by some confounding factors. These
variables should thus be collected regularly for the program
in future studies to more comprehensively explore the riskfactors of poor outcomes, and more accurately identify
high-risk patients who are enrolled in the pre-ESRD pro-
gram. However, despite these limitations, the findings of
this study remain important and useful for developing a
prevention policy for ESRD and predialysis mortality.
In summary, despite the progressive eGFR decline in
patients with CKD stages 3be5, especially in diabetic CKD,
our preliminary results suggest a lower eGFR declining rate
in patients enrolled in the Taiwan pre-ESRD disease man-
agement program. This study also identified the varying
probabilities and risk factors of CKD progressing to ESRD in
this program, suggesting that a more effective pre-ESRD
disease management program would be more than just a
renal program, and should instead utilize the integrated
efforts of various health professionals, such as di-
abetologists and cardiologists, to provide a more patient-
centered multidisciplinary program.
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